SCHEMBL1017314

SCHEMBL1017314

N#Cc1ccccc1-c1ccc2c(c1)CCN(CC(=O)N1CCN(C3CCC3)CC1)C2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 2/20 0.50
KDM2B Q8NHM5 1/20 0.43
PARP1 P09874 2/20 0.43
DPP8 Q6V1X1 1/20 0.43
PRMT5 O14744 2/20 0.42
WDR77 Q9BQA1 2/20 0.42
ALDH1A1 P00352 4/20 0.41
GAA P10253 1/20 0.41
PKM P14618 1/20 0.41
HSD17B10 Q99714 1/20 0.41
HSD17B3 P37058 1/20 0.41
KDM4E B2RXH2 3/20 0.40
MEN1 O00255 1/20 0.40
KCNH2 Q12809 2/20 0.40
HRH3 Q9Y5N1 1/20 0.40
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
KCNJ1 P48048 2/20 0.39
GPR84 Q9NQS5 1/20 0.38
MCHR1 Q99705 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1018047 0.86 ACHE (0.47) KDM2BPARP1PRMT5WDR77ALDH1A1
SCHEMBL1016153 0.85 ALDH1A1 (0.48) USP30PARP1ALDH1A1GAAPKM
SCHEMBL1017531 0.85 CD274 (0.44) KDM2BPARP1PRMT5WDR77ALDH1A1
SCHEMBL1015291 0.84 ACHE (0.47) KDM2BPARP1PRMT5WDR77ALDH1A1
SCHEMBL1016929 0.83 CD274 (0.48) PARP1ALDH1A1GAAPKMHSD17B10
SCHEMBL1016365 0.83 HRH3 (0.46) PARP1PRMT5WDR77ALDH1A1GAA
SCHEMBL1016764 0.83 CD274 (0.40) PARP1PRMT5WDR77ALDH1A1GAA
SCHEMBL1016795 0.83 MEN1 (0.50) ALDH1A1GAAPKMHSD17B10KDM4E
SCHEMBL1014859 0.83 KDM4E (0.50) PARP1ALDH1A1GAAPKMHSD17B10
SCHEMBL1019934 0.83 PRMT5 (0.42) USP30PARP1PRMT5WDR77ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US claimed
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
EP-1998620-B1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES NEUROGEN CORP (US) 2011-01-12 EP disclosed
EP-1998620-B1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES NEUROGEN CORP (US) 2011-01-12 EP disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed
WO-2007106349-A2 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues HRH3, HRH4, HRH1 USP30 3006/4885KDM2B 2055/4885PARP1 3633/4885
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 USP30 3006/4885KDM2B 2055/4885PARP1 3633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.